Clinical Obesity · 2021 · 54 citations · 23 references
MedicineEndocrinologyPharmacologyClinical PharmacologyMetabolic RegulationObesity PreventionDiabetes MellitusGlucagon TherapyGlucagon-like Peptide-1 Receptor AgonistsGlycemic ControlWeight LossWeight ManagementAgonist ActivityDouble-blind TrialsDual Incretin AgonistsGlucagon Receptor AgonismGlucagon Receptor AgonistsGlucagon TreatmentGlucagon-like Peptide 1 Receptor AgonismWeight Loss Efficacy
Summary Weight loss has been shown to improve metabolic parameters and cardiovascular risk in people with type 2 diabetes mellitus (T2DM). This phase 2 study evaluated the safety and efficacy of JNJ‐64565111, a dual agonist of GLP‐1 and glucagon receptors, in individuals with T2DM and class II/III obesity. In this randomized, double‐blind study, participants with T2DM (HbA1c 6.5%‐9.5%), body mass index of 35 to 50 kg/m 2 and stable weight were randomly assigned (1:1:1:1) to placebo or JNJ‐64565111 (5.0 mg, 7.4 mg or 10.0 mg). The primary endpoint was percent change from baseline in body weight at week 12. Of 195 dosed participants, 144 (73.8%) completed treatment. At week 12, placebo‐subtracted body weight changes were −4.6%, −5.9% and −7.2% with JNJ‐64565111 5.0 mg, 7.4 mg and 10.0 mg, respectively. All JNJ‐64565111 doses were associated with no change in HbA1c and slight numerical elevation of fasting insulin. Numerical increases in fasting plasma glucose were observed with JNJ‐64565111 5.0 mg and 7.4 mg. Incidence of treatment‐emergent adverse events, especially nausea and vomiting, was higher with JNJ‐64565111 vs placebo. Overall, JNJ‐64565111 significantly reduced body weight in a dose‐dependent manner vs placebo but was associated with greater incidence of treatment‐emergent adverse events, no HbA1c reductions, and increased fasting plasma glucose and fasting insulin.
23
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
June M. Chan, Eric B. Rimm, Graham A. Colditz et al. · Diabetes Care · 1994 · 1.8K citations · Full text
Effect of Weight Loss With Lifestyle Intervention on Risk of Diabetes
Richard F. Hamman, Rena R. Wing, Sharon L. Edelstein et al. · Diabetes Care · 2006 · 1.4K citations · Full text
Medicine, Chronic Disease Prevention, Preventive Medicine +17
Gut Hormones as Mediators of Appetite and Weight Loss After Roux-en-Y Gastric Bypass
Carel W. le Roux, Richard Welbourn, Malin Werling et al. · Annals of Surgery · 2007 · 738 citations